Filter posts

2016 Snapshot: BIO’s Top Five Health Blogs

There was no shortage of health hot topics this year, but as 2016 comes to …

BIO Releases Largest Study Ever on Clinical Development Success Rates

On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in …

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, …

BIO Submits Joint Supplemental Comments on the USPTO March Guidance

Last week BIO, alongside a number of member companies and private individuals, submitted supplemental comments …

Biotech Analyst Optimism: Price Targets Post-IPO

In a recent blog post, Bruce Booth of Life Sci VC, writes about the relationship …

Biotech Stocks: Perspective in a Bull Market

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong …

Debunking the Biotech Bubble Talk

The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a …

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

With 31 (and counting) life sciences companies having already placed IPOs on the market within …

The Return of the Biotech IPO

It isn’t just the volume of IPOs this summer that makes this window a victory …

Industry Growth Factor: Biologics

Last week, EvaluatePharma released their updated sales and R&D outlook for the drug industry in their …